Study of RO7250284 in Participants With Neovascular Age-Related Macular Degeneration
Status:
Recruiting
Trial end date:
2025-11-19
Target enrollment:
Participant gender:
Summary
This is a first in-human study to investigate the safety and tolerability of RO7250284
administered through intravitreal (IVT) injections and via the Port Delivery System in
participants with neovascular age-related macular degeneration (nAMD)